Search
Now showing items 1-10 of 36
Targeting HER2 expression in cancer: New drugs and new indications.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2020 , Article)
Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. ...
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
(
Lippincott, Williams & Wilkins
, 2019 , Article)
The breast is a rare site for metastases, and their molecular characteristics have not been studied yet. Intrinsic molecular genetics, cancer characteristics, and breast tissue immune responses in diverse metastases to the ...
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
(
Elsevier Ltd
, 2018 , Article)
Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ...
Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.
(
Public Library of Science
, 2018 , Article)
Olfactory neuroblastoma (ONB) is a rare, locally aggressive, malignant neoplasm originating in the olfactory epithelium in the nasal vault. The recurrence rate of ONB remains high and there are no specific treatment ...
Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
(
Wiley Open Access
, 2019 , Article)
Salivary duct carcinoma (SDC) is a rare, aggressive salivary gland malignancy, which often presents at an advanced stage. A proportion of SDC are characterized by HER2 amplification and/or overexpression of androgen receptor ...
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast
(
Elsevier
, 2021 , Article)
Apocrine carcinoma of the breast is a rare malignancy. According to 2019 WHO classification, apocrine cellular features and a characteristic steroid receptor profile (Estrogen receptor (ER)-negative and androgen receptor ...
Molecular characterization of cancers with NTRK gene fusions
(
Springer Nature
, 2019 , Article)
Targeted inhibitors of neurotropic tyrosine kinases are highly effective in selected patients with gene fusions involving NTRK1, NTRK2, or NTRK3. These fusions are consistently detected in rare cancer types (e.g., secretory ...
Molecular Profiling of Clear Cell Carcinoma of the Breast Reveals Novel Targetable Biomarkers
(
Springer Nature
, 2020 , Conference Paper)
Background: Although clear cell morphology may be seen in various subtypes of breast cancer, a pure variant of clear cell carcinoma (usually glycogen-rich) is a very rare primary breast malignancy. It is characterized by ...
Apocrine Carcinoma
(
Springer
, 2020 , Book chapter)
Carcinoma with apocrine differentiation (invasive apocrine carcinoma) is defined by “WHO Classification of Tumours of the Breast” as “any invasive carcinoma in which cells show the cytological features of apocrine ...